Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 February 12, 2026 9:30 AM ESTCompany ParticipantsJohn Butler ...
In a study, blocking the immune system complement protein C3 was shown to reduce MS disease severity in older mice but not in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results